Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Huibert M. Vriesendorp"'
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 19:43-51
Biodistribution studies demonstrate that intralesional administration of radiolabeled IgM results in high retention of radioactivity with little normal tissue uptake. This study examines the therapeutic potential of this modality.Nude mice bearing su
Autor:
Cynthia T. Wyllie, Karel A. Dicke, Syed M. Quadri, Huibert M. Vriesendorp, Borje S. Andersson
Publikováno v:
Cancer. 80:2721-2727
BACKGROUND. Indium-111 labeled antiferritin targets 95% of all Hodgkin's disease lesions with a diameter of 1 cm or more. Subsequent treatment with yttrium-90 labeled antiferritin secures a high response rate in patients with recurrent Hodgkin's dise
Autor:
Huibert M. Vriesendorp, Robyn E. Flynn, Francine J. Vriesendorp, Douglas M. Cromeens, L. Clifton Stephens, Syed M. Quadri, Michael R. Malone
Publikováno v:
Cancer. 80:2642-2649
BACKGROUND Unlabeled murine monoclonal anti-GD2 immunoglobulin (Ig)G (14G2a) reactive with nervous system diganglioside and neuroblastoma, melanoma, and small cell lung carcinoma produces tumor regression. However, serious acute abdominal pain, pares
Publikováno v:
Radiotherapy and Oncology. 44:283-293
Background and purpose : Intralesional (i.l.) administration of radiolabeled human monoclonal IgM could provide a new method for increasing the radiation dose delivered to a tumor without exceeding normal tissue tolerance. Materials and methods : Nud
Autor:
Douglas M. Cromeens, Huibert M. Vriesendorp, Ralph S. Freedman, Syed M. Quadri, Kurt A. Jaeckle
Publikováno v:
Radiotherapy and Oncology. 41:151-161
Background and purpose : Radiolabeled immunoglobulin therapy (RIT) can be a selective, effective, low-toxicity outpatient cancer therapy. A consensus on the best approach for the preclinical and clinical development of RIT reagents needs to be develo
Publikováno v:
Nuclear Medicine and Biology. 22:413-423
Unmodified F(ab′) 2 and modified Fab′-BMH-Fab′ fragments of human monoclonal IgM (16.88) were compared for biodistribution and tumor localization in nude mice bearing LS-174T human colon carcinoma xenografts. Although both unmodified and modifi
Autor:
C F LeMaistre, K. Van Besien, Meletios A. Dimopoulos, Issa F. Khouri, James Gajewski, Sergio Giralt, Huibert M. Vriesendorp, Rakesh Mehra, Donna Przepiorka, Borje S. Andersson
Publikováno v:
Journal of Clinical Oncology. 12:1923-1930
PURPOSE To determine the efficacy and toxicity of etoposide, cyclophosphamide, and fractionated total-body irradiation (TBI) as the conditioning regimen for allogeneic bone marrow transplantation (BMT) in patients with hematologic malignancies. PATIE
Fractionated intravenous administration of 90Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs
Publikováno v:
Nuclear Medicine and Biology. 20:571-578
B72.3, a monoclonal antibody with reactivity against human adenocarcinomas, was coupled with linker-chelator GYK-DTPA using carbohydrate mediated conjugation chemistry and radiolabeled with yttrium-90. Single and double intravenous injections of radi
Autor:
Peter K. Leichner, Ross A. Abrams, Karel A. Dicke, Jerry L. Klein, James O. Armitage, Julie M. Vose, Syed M. Quadri, Huibert M. Vriesendorp, Philip J. Bierman
Publikováno v:
Journal of Clinical Oncology. 11:698-703
PURPOSE This study was undertaken to examine the feasibility of combining radiolabeled antibody therapy with high-dose chemotherapy followed by autologous bone marrow transplantation in patients with poor-prognosis Hodgkin's disease. PATIENTS AND MET
Autor:
W. S. May, William H. Burns, Huibert M. Vriesendorp, S Piantadosi, Scott D. Rowley, Eric J. Seifter, Richard F. Ambinder, Risa B. Mann, Martin D. Abeloff, Richard J. Jones
Publikováno v:
Journal of Clinical Oncology. 8:527-537
Patients with Hodgkin's disease who have failed two or more chemotherapy regimens or who have relapsed after an initial chemotherapy-induced remission of less than 12 months are seldom cured with conventional salvage therapies. We studied the effect